Millipore Sigma Vibrant Logo

506069 InSolution™ EZH2 Inhibitor, DZNep - CAS 120964-45-6 - Calbiochem

A 25 mM (1 mg/98 µL) sterile-filtered solution of Histone Methyltransferase EZH2 Inhibitor, DZNep in H₂O.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: 3-Deazaneplanocin A, xHCl, yH₂O {x = 3 & y = 2}, (1S,2R,5R)-5-(4-Amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol, xHCl, yH₂O {x = 3 & y = 2}, NSC 617989

Primary Target: EZH2
View Products on Sigmaaldrich.com
506069
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
120964-45-6C₁₂H₁₄N₄O₃ • HCl

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
5060690001
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Flacon en verre 1 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      Catalogue Number506069
      Brand Family Calbiochem®
      Synonyms3-Deazaneplanocin A, xHCl, yH₂O {x = 3 & y = 2}, (1S,2R,5R)-5-(4-Amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol, xHCl, yH₂O {x = 3 & y = 2}, NSC 617989
      References
      ReferencesSun, F., et al. 2009. Mol. Cancer Ther. 8, 3191.
      Miranda, T.B., et al. 2009. Mol. Cancer Ther. 8, 1579.
      Fiscus, W., et al. 2009. Blood 13, 2733.
      Tan, J., et al. 2007. Genes Dev. 21, 1050.
      Chiang, P.K., et al. 1992. J. Biol. Chem. 267, 4988.
      Tseng, C.K., et al. 1989. J. Med. Chem. 32, 1442.
      Glazer, R.I., et al. 1986. Biochem. Biophys. Res. Commun. 135, 688.
      Product Information
      CAS number120964-45-6
      FormLiquid
      FormulationA 25 mM (1 mg/98 µL) sterile-filtered solution of Histone Methyltransferase EZH2 Inhibitor, DZNep (Cat. No. 252790) in H₂O.
      Hill FormulaC₁₂H₁₄N₄O₃ • HCl
      Chemical formulaC₁₂H₁₄N₄O₃ • HCl
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetEZH2
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Protect from Light Protect from light
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 monthst at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      5060690001 04055977243031

      Documentation

      InSolution™ EZH2 Inhibitor, DZNep - CAS 120964-45-6 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Références bibliographiques

      Aperçu de la référence bibliographique
      Sun, F., et al. 2009. Mol. Cancer Ther. 8, 3191.
      Miranda, T.B., et al. 2009. Mol. Cancer Ther. 8, 1579.
      Fiscus, W., et al. 2009. Blood 13, 2733.
      Tan, J., et al. 2007. Genes Dev. 21, 1050.
      Chiang, P.K., et al. 1992. J. Biol. Chem. 267, 4988.
      Tseng, C.K., et al. 1989. J. Med. Chem. 32, 1442.
      Glazer, R.I., et al. 1986. Biochem. Biophys. Res. Commun. 135, 688.

      Informations techniques

      Titre
      White Paper - The Message in the Marks: Deciphering Cancer Epigenetics
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision10-January-2014 JSW
      Synonyms3-Deazaneplanocin A, xHCl, yH₂O {x = 3 & y = 2}, (1S,2R,5R)-5-(4-Amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol, xHCl, yH₂O {x = 3 & y = 2}, NSC 617989
      DescriptionA cell-permeable compound that is shown (at 1 µM concentrations) to inhibit EZH2-mediated trimethylation of K27 on histone H3 and induces the expression of cell-cycle regulatory genes, p21 and p27, as well as the cell death regulator, FBXO32, in OCI-AML3 and HL-60 cells, whereby treatment with inhibitor increases p16 levels in the former, but not the latter of the two cultures. At concentrations between 200 nm and 2000 nM, this compound is found to dose-dependently deplete the expression of polycomb group proteins EZH2, SUZ12, and EED in cultured and primary AML cell extracts. At concentrations up to ≥ 1000 nM, DZNep dose-dependently increases the percentage of apoptotic cells up to > ~ 38%, with greater potency against OCI-AML3 than HL-60 cultures and inhibits colony growth up to > ~ 85% for both cell lines. In OCI-AML3 cultures, 1000 nM of treatment demonstrates a significant increase in the accumulation of cells in the G0/G1 phase (58.5%) with a concomitant decrease in the number of cells in S phase (35.2%) and G2/M phases (6.3%) of the cell cycle. When co-treated with panobinostat (PS), 200 nM to 1000nM DZNep is shown to decrease cell viability in OCI-AML3 and HL-60 cultures more effectively than DZNep alone, in a dose-dependent manner. DZNep (1mg/kg, twice per week, i.p.) and PS significantly prolong the survival of mice implanted with HL-60 cells compared to treatment with either compound alone. DZNep is also a known S-adenosyl-L-homocysteine (AdoHcy) hydrolase inhibitor.
      FormLiquid
      FormulationA 25 mM (1 mg/98 µL) sterile-filtered solution of Histone Methyltransferase EZH2 Inhibitor, DZNep (Cat. No. 252790) in H₂O.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number120964-45-6
      Chemical formulaC₁₂H₁₄N₄O₃ • HCl
      Purity≥98% by HPLC
      Storage Protect from light
      Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 monthst at -20°C.
      Toxicity Standard Handling
      ReferencesSun, F., et al. 2009. Mol. Cancer Ther. 8, 3191.
      Miranda, T.B., et al. 2009. Mol. Cancer Ther. 8, 1579.
      Fiscus, W., et al. 2009. Blood 13, 2733.
      Tan, J., et al. 2007. Genes Dev. 21, 1050.
      Chiang, P.K., et al. 1992. J. Biol. Chem. 267, 4988.
      Tseng, C.K., et al. 1989. J. Med. Chem. 32, 1442.
      Glazer, R.I., et al. 1986. Biochem. Biophys. Res. Commun. 135, 688.